1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant with HR 0.78. 2. Grade 2 or worse adverse events occurred 41% in the standard-of-care group vs 62% in the SBRT group. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment paradigm for metastatic cancer
AUA 2021: Clinically Relevant Questions in the Management of Locally Advanced and Oligometastatic Prostate Cancer urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.